Each participant underwent comprehensive ophthalmic examinations, including visual acuity and refractive error assessment, slit-lamp biomicroscopy, Goldmann applanation tonometry, gonioscopy, dilated stereoscopic examination of the optic disc, stereo disc photography, and red-free fundus photography (Kowa VX-10; Kowa Medicals, Torrance, CA, USA). Other ophthalmic examinations included scanning of the circumpapillary RNFL and the optic nerve head (ONH) using spectral-domain (SD) optical coherence tomography (OCT) (Spectralis OCT; Heidelberg Engineering, Heidelberg, Germany), and standard automated perimetry (Humphrey Field Analyzer II 750 and 24-2 Swedish interactive threshold algorithm; Carl Zeiss Meditec, Dublin, CA, USA). Subjects also underwent measurements of the corneal curvature (KR-1800; Topcon, Tokyo, Japan), central corneal thickness (CCT) (Orbscan II; Bausch & Lomb Surgical, Rochester, NY, USA), and axial length (AXL) (IOLMaster version 5; Carl Zeiss Meditec).
Subjects in the three groups were 1:1:1 matched by age, sex, and AXL. Participants underwent IOP measurement and optic disc scanning using enhanced depth imaging (EDI) SD-OCT in the baseline examination, which was performed prior to initiating ocular hypotensive treatment. The measured IOP was corrected for its dependence on the CCT. Definition of NTG, OHT, and healthy subjects, criteria for inclusion and exclusion, and the measurement and correction of IOP are described in the Appendix in the
Supplementary material.